Systemic therapy for pretreated advanced biliary tract cancer: past developments and recent advances
Naohiro Okano(Kyorin University), Shuichi Hironaka(Kyorin University), Mitesh J. Borad(Jacksonville College), Fumio Nagashima(Kyorin University), Binbin Zheng-Lin(WinnMed), Cody Eslinger(WinnMed), Masato Hayashi(Kanazawa University), Pedro Luiz Serrano Usón(Hospital Israelita Albert Einstein), Mohamad Bassam Sonbol(WinnMed), Mariko Nishioka(Kyorin University), Celine Hoyek(Mayo Clinic Hospital), Tanios Bekaii-Saab, Taro Sato(Kyorin University), Fares Jamal(WinnMed), Angelo Pirozzi(Humanitas University), Oudai Sahwan(Mayo Clinic in Arizona), Oluseyi Abidoye(Mayo Clinic)
Cited by 1
Related Papers
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
|Cell Reports|2017|619
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423